Intermittent Fasting vs Low-Calorie Diet in Managing Metabolic-Associated Fatty Liver Disease: Comparative Effects on Inflammation, Lipids, Glycemic Control, and Liver Fibrosis
Posted inClinical Updates Wellness & Lifestyle

Intermittent Fasting vs Low-Calorie Diet in Managing Metabolic-Associated Fatty Liver Disease: Comparative Effects on Inflammation, Lipids, Glycemic Control, and Liver Fibrosis

This RCT compares 16:8 intermittent fasting and low-calorie diets in MAFLD patients, revealing both improve liver enzymes and anthropometrics, but low-calorie diet shows superior reduction in liver steatosis, fibrosis, and triglycerides.
Afimkibart, an Anti-TL1A Antibody, in Moderately-to-Severely Active Ulcerative Colitis: Insights from the Phase 2b TUSCANY-2 Trial
Posted inClinical Updates Wellness & Lifestyle

Afimkibart, an Anti-TL1A Antibody, in Moderately-to-Severely Active Ulcerative Colitis: Insights from the Phase 2b TUSCANY-2 Trial

The TUSCANY-2 phase 2b trial evaluated afimkibart, a novel anti-TL1A antibody, in moderately-to-severely active ulcerative colitis, demonstrating favorable safety and clinically meaningful remission rates using modified Mayo scores despite primary endpoint statistical thresholds not being met by total Mayo scores.
Comparative Efficacy of Low FODMAP Plus Traditional Dietary Advice, Low-Carbohydrate Diet, and Pharmacological Treatment in Moderate-to-Severe IBS: Insights from the CARIBS Trial
Posted inClinical Updates Wellness & Lifestyle

Comparative Efficacy of Low FODMAP Plus Traditional Dietary Advice, Low-Carbohydrate Diet, and Pharmacological Treatment in Moderate-to-Severe IBS: Insights from the CARIBS Trial

The CARIBS trial shows that both low FODMAP plus traditional dietary advice and a low-carbohydrate diet outperform optimized pharmacologic treatment in reducing IBS symptom severity after 4 weeks, highlighting the importance of dietary interventions as first-line therapy.
Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Insights from a Large French Observational Study
Posted inClinical Updates Wellness & Lifestyle

Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Insights from a Large French Observational Study

A national French study reveals that cold agglutinin syndrome (CAS) develops about 10 days after Mycoplasma pneumoniae infection onset, often requiring ICU care and transfusions, with a generally favorable prognosis despite frequent venous thromboembolism and no clear benefit from glucocorticoid treatment.